Zu den Inhalten springen

Tumorzentrum Freiburg - CCCF

Ann-Christin Eder, PhD

Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), partner site Freiburg

Department of Nuclear Medicine, University Medical Center, Freiburg, Germany

Head of Biotechnological Development and Preclinical Imaging

Project: Development and translation of novel theranostic hybrid molecules for pre-, intra-, and postoperative diagnosis and therapy of cancer

Our research is focusing on identifying new biomarkers for the classification of tumors, assessing metastasizing potential and monitoring therapy. In particular my group is working on the development of small molecule peptides with a strong focus on hybrid molecules suitable for preoperative imaging, intraoperative navigation as well as for targeted endoradiotherapy of different cancer types. Therefore, we are using innovative biological, biotechnological and chemical approaches to identify novel peptides to a variety of clinically relevant target structures. Our development pipeline comprises the identification of potential binders, their detailed preclinical characterization including imaging studies finally leading to clinical translation.


  • Schmeiser HH, Muehlbauer KR, Mier W., Baranski AC, Neels O., Dimitrakopoulou-Strauss A., Schmezer P., Kratochwil C., Bruchertseifer F., Morgenstern A., Kopka K.; DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay. Mutagenesis. 2019 May 20
  • Tönnesmann, R., Meyer, P.T., Eder, M., Baranski, AC.: [177Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography. Pharmaceuticals 2019, 12(1),18.
  • Eder, M., Pavan, S., Bauder-Wüst, U., van Rietschoten, K., Baranski, AC, Harrison, H., Campbell, S., Stace, CL., Walker, EH., Chen, L., Bennett, G., Mudd, G., Schierbaum, U., Leotta, K., Haberkorn, U., Kopka, K., Teufel, DP.: Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors. Cancer Res. 2019 Feb 15;79(4):841-852.
  • Wohak LE*, Baranski AC*, Krais AM, Schmeiser HH, Phillips DH, Arlt VM: The impact of p53 function on the metabolic activation of the carcinogenic air pollutant 3-nitrobenzanthrone and its metabolites 3-aminobenzanthrone and N-hydroxy-3-aminobenzanthrone in human cells. Mutagenesis. 2018 Oct 11; 33(4):311-321; * these authors contributed equally to the work
  • Baranski AC, Schäfer M, Bauder-Wüst U, Roscher M, Schmidt J, Stenau E, Simpfendörfer T, Teber D, Maier-Hein L, Hadaschik B, Haberkorn U, Eder M, Kopka K.: PSMA-11–Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer. J Nucl Med. 2018 Apr; 59(4): 639-645
  • Baranski AC, Schäfer M, Bauder-Wüst U, Wacker A, Schmidt J, Liolios C, Mier W, Haberkorn U, Eisenhut M, Kopka K, Eder M.: Improving the Imaging Contrast of 68Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties. Bioconjug Chem. 2017 Sep 20; 28(9):2485-2492
  • Wild E, Teber D, Schmid D, Simpfendörfer T, Müller M, Baranski AC, Kenngott H, Kopka K, Maier-Hein L.: Robust augmented reality guidance with fluorescent markers in laparoscopic surgery. Int J Comput Assist Radiol Surg.; 11(6):899-907

-- Logo: © dkfz.de


School of Oncology DKTK

SoO DKTK Homepage